Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis

Masarova Lucia; Kantarjian Hagop M.; Verstovsek Srdan

首页> 外文期刊>Clinical lymphoma, myeloma & leukemia >Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis

【24h】

Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis

机译：升高的外周血（4-9％）和骨髓爆炸（5-9％）与初级髓颤患者的预后差以及后基质血小板血症和多胆后血症后血糖血肿（5-9％）有关

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical lymphoma, myeloma & leukemia》 |2017年第10suppla期|共1页
作者
Masarova Lucia; Kantarjian Hagop M.; Verstovsek Srdan;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis [J] . Masarova Lucia, Kantarjian Hagop M., Verstovsek Srdan Clinical lymphoma, myeloma & leukemia . 2017,第10Suppla期

机译：升高的外周血（4-9％）和骨髓爆炸（5-9％）与初级髓颤患者的预后差以及后基质血小板血症和多胆后血症后血糖血肿（5-9％）有关
2. The Evolving Understanding of Prognosis in Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis [J] . Lucia Masarova, Srdan Verstovsek Clinical advances in hematology & oncology: H&O . 2019,第5期

机译：在基本基本血小板血症和多胆后血症后的预后的不断变化的理解Vera Myelofibris对原发性髓颤
3. Population pharmacokinetic analysis of orally-administered ruxolitinib (incb018424 phosphate) in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF) [J] . ChenX., WilliamsW.V., SandorV., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2013,第7期

机译：原发性骨髓纤维化（pmf），真性红细胞增多症后真性骨髓纤维化（PPV-MF）或实质性血小板增多性骨髓炎（PET MF）患者口服ruxolitinib（incb018424磷酸盐）的群体药代动力学分析
4. Minimal Residual Disease in Bone Marrow and Peripheral Blood of Patients with Metastatic Breast Cancer [C] . Joachim Bischoff, Wolfgang Janni, Michael Dahm, International Meeting on Molecular Staging on Cancer . 2003

机译：转移性乳腺癌患者骨髓和外周血中的最小残留疾病
5. Environmental Etiology of Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis: A Case-Control Study in Northeast Pennsylvania. [D] . Gross-Davis, Carol Ann. 2014

机译：真性红细胞增多症，原发性血小板增多症和原发性骨髓纤维化的环境病因：宾夕法尼亚州东北部的病例对照研究。
6. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis [O] . A Tefferi, L Saeed, C A Hanson, -1

机译：当前原发性骨髓纤维化的预后模型在真性红细胞增多症或实质性血小板增多性骨髓纤维化之后的应用
7. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ [O] . Francesca Palandri, Giuseppe A. Palumbo, Alessandra Iurlo, 2018

机译：用Ruxolitinib治疗原发性髓OERIBIB病患者和/或多胆症后血小心患者的特征，结果和预后模型的差异。大型多中心研究中的Mysec-PM的新视角

Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis

著录项

相似文献

相关主题

期刊订阅